LAG3 and cancer: Furthermore, the advancement of next-generation ICIs targeting novel pathways, including “Lymphocyte Activation Gene-3 (LAG-3), T-cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), and T-cell Immunoreceptor with Ig and ITIM domains (TIGIT)”, provides new opportunities for patients with treatment-resistant cancers or those unresponsive to existing therapies [29,30].